Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1191

Sort by

Sort Order Select

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

Haploidentical Transplantation Using Double Source of Hematopoietic Stem Cells and Post-Transplant Cyclophosphamide for Acute Leukemias

Ana Marcela Rojas Fonseca-Hial, Katya Parisio, MD, José Salvador Rodrigues de Oliveira, MD PhD

Blood (2019) 134 (Supplement_1): 5728.

https://doi.org/10.1182/blood-2019-130876

Published: 2019

Journal Articles

A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)

Mrinal M Patnaik, MDMBBS, David A Sallman, MD, Abhishek A Mangaonkar, MBBS, Rachel Heuer, Jeffery Hirvela, Darci Zblewski, APRN, C-NP, Aref Al-Kali, MD, Deanna Kanne, Rahil Ismail, Rami S. Komrokji, MD, Adrian Lo, Maria E Balasis, Cameron Durrant, Dale Chappell, Omar Ahmed, Alan F. List, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 4234.

https://doi.org/10.1182/blood-2019-131181

Published: 2019

Journal Articles

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Jiasheng Wang, MD, Kirsten M Boughan, DO, Paolo F Caimi, MD, Brenda Cooper, MD, Marcos de Lima, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Shufen Cao, Pingfu Fu, PhD, Benjamin Tomlinson, MD

Blood (2019) 134 (Supplement_1): 2607.

https://doi.org/10.1182/blood-2019-131293

Published: 2019

Journal Articles

The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type

Hyera Kim, Eo Jin Kim, Sang Eun Yoon, Youngil Koh, Dok Hyun Yoon, Seok Jin Kim, MD PhD, Sung-Soo Yoon, MD PhD, Hong Ghi Lee, Won Seog Kim, MD PhD

Blood (2019) 134 (Supplement_1): 2847.

https://doi.org/10.1182/blood-2019-128154

Published: 2019

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial

Meera Yogarajah, MD, William J Hogan, MB, BCh, Naseema Gangat, MBBS, Dong Chen, MD PhD, Rong He, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mrinal M Patnaik, MDMBBS, Michelle A Elliott, MD, Mark Litzow, MD, Aref Al-Kali, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Kebede H. Begna, MD

Blood (2019) 134 (Supplement_1): 3863.

https://doi.org/10.1182/blood-2019-125361

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

https://doi.org/10.1182/blood-2019-122070

Published: 2019

Journal Articles

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Ariela Noy, MD, Timothy S. Pardee, MD PhD, Liana Nikolaenko, MD, Raphael Eric Steiner, MD, Jeremy S. Abramson, MD MMSc, Kieron Dunleavy, MD, Sanjeev Luther, MBA

Blood (2019) 134 (Supplement_1): 4087.

https://doi.org/10.1182/blood-2019-131563

Published: 2019

Journal Articles

Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors

Jose ROS Soto, MBBS, Eva Zoubek, PhD, Richard Szydlo, PhD, Paul Johnson, Ann O'Leary, Maria Del Mar Cuadrado, MBBS, Catherine Burlton, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath, Chloe Anthias, MD

Blood (2019) 134 (Supplement_1): 3249.

https://doi.org/10.1182/blood-2019-122304

Published: 2019

Journal Articles

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Samantha C Fisch, BS, Brian A Jonas, MD PhD, Joseph Tuscano, MD, Aaron Seth Rosenberg, MD, Rasmus T Hoeg, MD, Mehrdad Abedi, MD

Blood (2019) 134 (Supplement_1): 3884.

https://doi.org/10.1182/blood-2019-121991

Published: 2019

Journal Articles

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients

Cole Sterling, MD, Nina D. Wagner-Johnston, MD, Douglas E Gladstone, MD, Richard F. Ambinder, MD, Lode J. Swinnen, MB ChB, Philip Hollingsworth Imus, MD

Blood (2019) 134 (Supplement_1): 3342.

https://doi.org/10.1182/blood-2019-126253

Published: 2019

Journal Articles

Vδ1+ T Cells: Adoptive Cell Therapy for the Treatment of Haematological Malignancies in Allogeneic Settings

André Simoes, PhD, Joanna Kawalkowska, PhD, Timothy Recaldin, PhD, Daniel Foxler, PhD, Oliver Nussbaumer, PhD, Michael Koslowski, MD

Blood (2019) 134 (Supplement_1): 3221.

https://doi.org/10.1182/blood-2019-125688

Published: 2019

Journal Articles

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Douglas W. Blayney, MD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2019) 134 (Supplement_1): 4861.

https://doi.org/10.1182/blood-2019-127227

Published: 2019

Journal Articles

Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation

Chenglong Li, MDand PhD, Xi Yang, Jingying Dai, PhD, Ningning Tang, Hong Zheng, MD PhD, Chunsen Wang, MD, Xiaobing Huang

Blood (2019) 134 (Supplement_1): 1966.

https://doi.org/10.1182/blood-2019-126632

Published: 2019

Journal Articles

A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)

Douglas W. Blayney, MD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2019) 134 (Supplement_1): 3590.

https://doi.org/10.1182/blood-2019-127310

Published: 2019

Journal Articles

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Kelly Gaffney, PharmD, Brian P. Hobbs, PhD, Ran Zhao, Marc Earl, PharmD, Marina Feldman, PharmD, BCCCP, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MD MS, Bhumika J. Patel, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2019) 134 (Supplement_1): 3433.

https://doi.org/10.1182/blood-2019-128807

Published: 2019

Journal Articles

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Jorge Monge, MD, Jorge Contreras, MD, Sarah Elsoukkary, MD, Jin Guo, MD, Art Perry, PA, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Morton Coleman, MD, Adriana C. Rossi, MDMSc, Rebecca Harris, MD, Markus Plate, MD, Joerg-Patrick Stuebgen, MB, ChB, MD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 4876.

https://doi.org/10.1182/blood-2019-122134

Published: 2019

Journal Articles

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Luca Biavati, MD, Anna Ferguson, BSN, RN, Carol Ann Huff, MD, Lakshmi Rudraraju, MS, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Syed Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD

Blood (2019) 134 (Supplement_1): 1895.

https://doi.org/10.1182/blood-2019-128430

Published: 2019

NARROW

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Haploidentical Transplantation Using Double Source of Hematopoietic Stem Cells and Post-Transplant Cyclophosphamide for Acute Leukemias

A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients

Vδ1+ T Cells: Adoptive Cell Therapy for the Treatment of Haematological Malignancies in Allogeneic Settings

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation

A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only